Alnylam Pharmaceuticals (ALNY) EPS (Diluted) Growth (3y) (2022 - 2026)
Alnylam Pharmaceuticals (ALNY) EPS (Diluted) Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 78.99% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 37.28% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.39% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -2.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 83.94% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 45.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.22% |
| Dec 31, 2025 | 35.46% |
| Sep 30, 2025 | 38.23% |
| Jun 30, 2025 | 39.53% |
| Mar 31, 2025 | 58.69% |
| Dec 31, 2024 | 33.00% |
| Sep 30, 2024 | 20.34% |
| Jun 30, 2024 | 56.41% |
| Mar 31, 2024 | 32.65% |
| Dec 31, 2023 | 19.53% |
| Sep 30, 2023 | 35.99% |
| Jun 30, 2023 | -12.39% |
| Mar 31, 2023 | 5.60% |
| Dec 31, 2022 | 12.30% |